Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

SEHK:1349 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
08 May 24	SellHK$788,570	Invesco Ltd.	Company		364,000	HK$2.17

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1349?
Owner Type	Number of Shares	Ownership Percentage
Institutions	38,348,396	3.7%
VC/PE Firms	156,892,912	15.1%
Public Companies	210,142,560	20.3%
Individual Insiders	266,675,430	25.7%
General Public	364,512,802	35.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 64.83% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
20.3%	Shanghai Pharmaceuticals Holding Co., Ltd	210,142,560	HK$1.4b	-25.1%	no data
15.1%	China New Enterprise Investment Co., Ltd.	156,892,912	HK$1.1b	0%	no data
7.72%	Zong Meng Yang	80,000,000	HK$540.8m	0%	no data
7.52%	Chong Mang Ieong	77,958,092	HK$527.0m	0%	no data
5.58%	Hai Bo Wang	57,886,430	HK$391.3m	0%	no data
1.78%	Yong Su	18,477,860	HK$124.9m	0%	no data
1.56%	Invesco Ltd.	16,160,000	HK$109.2m	0%	no data
1.51%	Da Jun Zhao	15,620,710	HK$105.6m	0%	no data
0.87%	Jun Li	9,018,200	HK$61.0m	0%	no data
0.63%	Shanghai Pudong Science and Technology Investment Co., Ltd.	6,562,382	HK$44.4m	0%	1.36%
0.63%	Shanghai Pudong Emerging Industry Investment Co., Ltd.	6,562,382	HK$44.4m	0%	no data
0.44%	Gfund Management Co., Ltd.	4,532,842	HK$30.6m	0%	0.14%
0.28%	Dimensional Fund Advisors LP	2,906,014	HK$19.6m	0%	no data
0.2%	Xue Yan	2,030,000	HK$13.7m	0%	no data
0.18%	Xiaolin Yang	1,845,688	HK$12.5m	0%	no data
0.15%	Yi Min Gan	1,572,850	HK$10.6m	0%	no data
0.11%	Luo Chun Wang	1,170,000	HK$7.9m	0%	no data
0.1%	Fullgoal Fund Management Co. Ltd.	1,062,144	HK$7.2m	0%	no data
0.064%	Dai Qing Yu	664,000	HK$4.5m	0%	no data
0.025%	E Fund Management Co., Ltd.	261,407	HK$1.8m	0%	no data
0.02%	Xiaowen Li	210,000	HK$1.4m	0%	no data
0.018%	Yu Chen	182,600	HK$1.2m	0%	no data
0.012%	Penghua Fund Management Co., Ltd.	128,815	HK$871.0k	0%	no data
0.0075%	Tebon Fund Management Co. Ltd.	77,700	HK$525.6k	0%	0.01%
0.0038%	Ya Nan Qu	39,000	HK$263.5k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 16:18
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Hu	Deutsche Bank
Feng Qiang Sun	Guotai Junan International Holdings Limited
Xiang Jun	Industrial Securities Co. Ltd.